Spots Global Cancer Trial Database for Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)
Official Title: A Phase II Study to Investigate the Efficacy and Tolerability of Vorinostat in Patients Suffering From Advanced, Metastatic Soft Tissue Sarcoma
Study ID: NCT00918489
Conditions
Interventions
Study Description
Brief Summary: Primary objective of the study is to investigate the efficacy of vorinostat in patients suffering from selected histological types of soft tissue sarcoma. Further evaluations relate to the safety and tolerability of vorinostat, its pharmacokinetics (course of plasma concentration over time) and pharmacodynamics (mode of action). Only subjects with advanced, metastatic disease will be included in this trail.
Detailed Description: The treatment with vorinostat will be administered daily over 28 days. This period will be referred to as a therapy cycle. Two consecutive therapy cycles will be separated by a 7-days therapy break. In case of a good response and no relevant side effects, the treatment with vorinostat can be continued for up to 1 year after begin of the treatment. If any relevant side effects or intolerability occur, the dose and/or schedule of administration will be modified according to the pre-defined criteria.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Hematology, Oncology, Rheumatology and Immunology, University Hospital Tübingen, Tübingen, Baden-Württemberg, Germany
Department of Hematology, Hemostaseology, Oncology and Stemm Cell Transplantation, Medical School Hannover, Hannover, Niedersachen, Germany
Department of Oncology, Hematology and Palliative Medicine, Marien Hospital Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany
Comprehensive Cancer Center North, University Hospital Kiel, Kiel, , Germany
Sarcoma Center Mannheim, University Hospital Mannheim, Mannheim, , Germany
Center for Soft Tissue Sarcoma, University Hospital Tübingen, Tübingen, , Germany
Comprehensive Cancer Center Ulm (CCCU), Ulm, , Germany
Contact Details
Name: Gerlinde Egerer, MD
Affiliation: Department of Internal Medicine V, Universtity Hospital Heidelberg
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
